CD276 and breast carcinoma: The American Joint Committee on Cancer evaluated B7-H3 expression in stage I to III primary breast cancer and normal breast specimens, results showed that 39% of initial breast cancers had B7-H3 mRNA expression, whereas normal breast tissues did not [26].